For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Monogram Biosciences, Inc.

USPTO Granted Patents = 52

CIPO Patents = 4

EPO Patents = 15

Trademarks = 11

Forward Citations = 719

Loading Chart...

Loading Chart...

55 inventors (with patents filed for the assignee):

Sharat Singh (19 out of 62 patents)

Neil T Parkin (15 out of 22 patents)

Christos J Petropoulos (13 out of 20 patents)

4. Wei Huang (12 out of 34 patents)

5. Po-Ying Chan-Hui (10 out of 27 patents)

6. Hossein Salimi-Moosavi (9 out of 11 patents)

7. Hrair Kirakossian (8 out of 24 patents)

8. Rajiv Dua (7 out of 13 patents)

9. Sailaja Pidaparthi (7 out of 7 patents)

10. Yining Shi (7 out of 7 patents)

11. Tracy J Matray (5 out of 15 patents)

12. Gerald J Wallweber (4 out of 10 patents)

13. Colombe Chappey (4 out of 4 patents)

14. Jeannette Whitcomb (4 out of 9 patents)

15. Mary T Wrin (4 out of 5 patents)

Core Competencies:

HIV Entry Inhibitors

Viral Resistance Determination

Recombinant Virus Assays

Her2 Diagnostics

Protein Analysis

Coreceptor Inhibitors

Molecular Complex Profiling

Protease Inhibitor Susceptibility

Receptor Tyrosine Kinase Signaling

Antiviral Drug Screening

Hypersusceptibility Assessment

Multiplexed Assay Techniques

52 patents: Sort by Forward Citations

1. 11499200 - Methods for determining resistance or susceptibility to HIV entry inhibitors (2022-11-15),

2. 11459624 - Compositions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays (2022-10-04),

3. 10550441 - Compositions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays (2020-02-04),

4. 10416162 - Her2 diagnostic methods (2019-09-17),

5. 10385411 - Methods for determining resistance or susceptibility to HIV entry inhibitors (2019-08-20),

6. 10202658 - Methods for determining hypersusceptibility of HIV-1 to non-nucleoside reverse transcriptase inhibitors (2019-02-12),

7. 10161931 - Methods for determining susceptibility to coreceptor inhibitors (2018-12-25),

8. 9939447 - Methods and compositions for analyzing proteins (2018-04-10),

9. 9841425 - Methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays (2017-12-12),

10. 9506121 - Methods for determining resistance or susceptibility to HIV entry inhibitors (2016-11-29),

11. 9493847 - Molecular determinants in the HIV-1 envelope associated with enhanced ability to enter CXCR4-expressing cells (2016-11-15),

12. 9175355 - Methods for determining the presence of antibodies blocking viral infection (2015-11-03),

13. 9110075 - Compositions for analyzing proteins (2015-08-18),

14. 8637252 - Methods and compositions for determining altered susceptibility of HIV-1 to anti-HIV drugs (2014-01-28),

15. 8603736 - Compositions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays (2013-12-10),

Monogram BioSciences, Inc. is a biotechnology company specializing in the development and commercialization of innovative diagnostic products. With a focus on personalized medicine, Monogram BioSciences delivers molecular diagnostic solutions that enable healthcare professionals to make informed treatment decisions. From their extensive research and development efforts, Monogram BioSciences has established itself as a leader in the field, providing cutting-edge tools and technologies for improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

52 Patents

#24 in South San Francisco, CA

#1,546 in California

#6,544 in US

#13,161 in the World

South San Francisco, CA, United States of America

Monogram Biosciences, Inc.

Forward Citations = 719

55 inventors:

Sharat Singh (19 out of 62 patents)

Neil T Parkin (15 out of 22 patents)

Christos J Petropoulos (13 out of 20 patents)

4. Wei Huang (12 out of 34 patents)

5. Po-Ying Chan-Hui (10 out of 27 patents)

Please report any incorrect information to support@idiyas.com

Loading…